Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

TVI Pacific files 2025 audited financials but delays 2026 interim reports, trading remains halted.

Company Fundamentals
02 Jun 2026
Newsfile Corp
View Source
Neutral
pluang ai news

TVI Pacific Inc. filed its annual audited financial statements for 2025 on June 2, 2026, but has yet to file its interim unaudited financials for Q1 2026, expected by June 12, 2026. Due to the late filing, the Alberta Securities Commission issued a management cease trade order (MCTO) starting May 4, 2026, extended until June 16, 2026. TVI's management will continue to halt trading of its securities until all required filings are submitted. The company remains in default but is providing bi-weekly status updates as it works to comply with regulations.

More News

Cornerstone expands free sustainability data with updated EPA GHG Emission Factors Hub for scopes 1, 2, and 3 emissions.

Cornerstone expands free sustainability data with updated EPA GHG Emission Factors Hub for scopes 1, 2, and 3 emissions.

Cornerstone has released an updated version of the EPA's GHG Emission Factors Hub, providing free, consolidated data for scopes 1, 2, and 3 greenhouse gas emissions. This update includes new factors for air travel, refrigerants, and aligns with the l...

Others
Bullish
57 minutes ago
New data show Lyell's ronde-cel CAR T-cell therapy is safe and effective for large B-cell lymphoma.

New data show Lyell's ronde-cel CAR T-cell therapy is safe and effective for large B-cell lymphoma.

Lyell Immunopharma presented updated safety and translational data for its CAR T-cell therapy, ronde-cel, in treating relapsed or refractory large B-cell lymphoma (LBCL). Over 100 patients treated showed no severe cytokine release syndrome (CRS) and ...

Market News
Bullish
1 hour ago
Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock.

Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock.

Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, all...

Company Fundamentals
Bullish
1 hour ago
SpaceX shares debut at $150, rising to $165, valuing the company near $2 trillion.

SpaceX shares debut at $150, rising to $165, valuing the company near $2 trillion.

SpaceX began trading on the stock market at $150 per share, above its IPO price of $135, marking the largest public offering in history and valuing the company at about $1.96 trillion. The shares quickly rose to $165, reflecting strong demand that ex...

Market News
Bullish
1 hour ago
Space ETFs drop sharply as SpaceX debuts in record $1.77T IPO, investors rotate funds into the new stock.

Space ETFs drop sharply as SpaceX debuts in record $1.77T IPO, investors rotate funds into the new stock.

Space ETFs fell significantly on the day SpaceX launched its IPO, priced at $135 per share with a $1.77 trillion valuation, raising $75 billion in the largest IPO ever. The sell-off reflects investors rotating out of other space stocks to buy SpaceX ...

Market News
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App